31results about How to "Reduce the degree of edema" patented technology

The invention relates to an application of zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder in preparation of medicines for healing skin wounds. The zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder is prepared from the following raw materials in parts by mass: 5-10 parts of zinc-based montmorillonite and 8-12 parts of calcium-based montmorillonite. According to the invention, zinc-based montmorillonite and calcium-based montmorillonite are used as effective ingredients of the medicament provided by the invention, and the effective ingredients are combined with pharmaceutical auxiliary materials to be prepared into the medicament through the processes of high-temperature dry heat sterilization, mixing, sterile sub-packaging and the like. Through skin external administration, the medicament can be used for quickly coagulating blood and arresting bleeding as well as preventing wound infection, has anti-bacterial and anti-inflammatory effects, and has converging and healing effects on the injured skin.

The invention discloses a drug compound of danshen root or the extract and cassia twig or the extract and the preparation method, the application of preparing drugs used for cardiovascular and cerebral diseases and the formulation containing the drug compound, belonging to the medical technical field. Measured by weight, the raw material drugs for preparing the effective components in the drug compound are as follow: 200 to 5000 for danshen root, 100 to 2000 for cassia twig; or 3 to 100 for the extract of the danshen root and 1 to 30 for the extract of cassia twig. The drug compound can be made into any acceptable clinical or pharmaceutical formulation; formulation for oral use or injection is preferred. The invention has the advantages that: the two drugs in the compound have the synergistic interaction function and jointly play the role of anti-myocardial ischemia, anti-thrombosis and resisting brain ischemia reperfusion injury, thereby the treating effect is improved greatly compared to singly using danshen root or the extract and cassia twig or the extract.

The invention relates to the application of tilorone in preparing a medicine for reducing hemorrhagic stroke cerebral edema. Experiments show that the tilorone remarkably upregulates an IFN-related gene in mouse brain. In a collagenase-induced cerebral hemorrhage model, the tilorone obviously reduces the cerebral edema degree of a model mouse. Therefore, the types of application diseases of the tilorone are further enlarged, and new medicine selection is also provided for preventing and treating the cerebral edema of hemorrhagic stroke patients.

The invention discloses application of a calycosin derivative in preparing a medicine for treating cerebral ischemia reperfusion injury. Through experiments, an applicant discovers that the calycosin derivative can up-regulate expression levels of ERalpha and GPR30, and can be more beneficial to reducing a neurological function score, reducing a cerebral infarction volume and reducing a cerebral oedema degree compared with calycosin; the calycosin derivative can dose-dependently up-regulate an ERK1 / 2 and Akt phosphorylation level, and plays a role in protecting an ischemia reperfusion injury nerve cell. The calycosin derivative has a structure as shown in the formula (I) which is shown in the description.

The invention discloses a medicine for treating ischemic cerebral arterial thrombosis, of which the active component is Z-octadecyl-9-alkenyl-propylsulfamide being 80-250 mg / kg in effective dose. The medicine is used in an oral manner. The active component of the medicine is the Z-octadecyl-9-alkenyl-propylsulfamide so that the medicine has a significant effect of treating the ischemic cerebral arterial thrombosis, can improve neurological deficit of mice, can reduce cerebral infarction volume and can alleviate the degree of encephaledema.

The present invention relates to the effect of azadirachtin in the preparation of drugs for promoting the survival of random skin flaps with ischemia. In the process of promoting the survival of random skin flaps with ischemia, it is taken orally. The dosage is 100 mg / kg or 200 mg / kg per day. 5-7 days is a course of treatment. Through a large number of animal experiments, it is concluded that the use of azadirachtin can significantly increase the survival area ratio of super long random skin flaps, reduce inflammation, improve antioxidant capacity, and greatly increase blood vessel density. Greatly promotes survival of ischemic random flaps.

The invention discloses a formula of traditional Chinese medicines for treating soft tissue injury and a method for preparing a preparation thereof. The formula comprises the following six traditional Chinese medicines in parts by weight according to mixture ratio: 3-9 parts of ceratostigma willmottianum, 1-5 parts of hyacinth bletilla, 1-5 parts of Gaultheria yunnanensis, 0.1-0.5 part of dragon's blood, 0.5-2 parts of turpentine and 0.3-2 parts of borneol which are prepared into an externally-applied traditional Chinese medicine preparation. The prepared externally-applied traditional Chinese medicine preparation is a spraying agent, a tincture, a liniment or a film coating agent. The result of experiments shows that the invention has the advantages of no irritability, no hypersensitivity, quick acting of the medicines, obvious effects of promoting the restoration of the injured soft tissues, resisting inflammation and relieving pain and the like. The preparation prepared by the invention enriches the active components of the medicines highly, has convenient carrying and use and accurate use dose and overcomes the defects of low content of effective components, difficult quality control, poor stability and the like.

The invention relates to a zinc-based montmorillonite aseptic band-aid and its preparation method and application. The band-aid includes a base cloth, an inner pad and an adhesive part, and a medicament is attached to the inner pad. It is characterized in that the medicament contains zinc base montmorillonite. The zinc-based montmorillonite used in the present invention can dissociate free zinc ions and montmorillonite, and the medicament surface of the band-aid is pasted on the skin wound, and the montmorillonite dissociated from the zinc-based montmorillonite in the band-aid meets After the blood is absorbed, a gel will be formed to stop the bleeding quickly; the formed gel can be used as a protective layer on the surface of the wound and around it to prevent the invasion of external bacteria; the zinc ions dissociated from zinc-based montmorillonite have antibacterial and anti-inflammatory effects, It also has astringent and healing effects on damaged skin.

The present disclosure provides a device for preventing and eliminating edema of an affected limb, an auxiliary motion system, and a working method, which relate to the field of medical equipment, and include a flexible sleeve with an electric heating mechanism, the sleeve is matched with a bracket, and the bracket is rotatably matched with a parallel sleeve parallel to the sleeve. The reel of the busbar on the outer wall of the cylinder, the reel and the sleeve are jointly equipped with a restraint belt. One end of the restraint belt is fixed on the outer side of the sleeve, and the other end is wound around the sleeve and then wound on the reel. The reel is used to tighten or tighten by rotating. Loosen the part where the restraint belt is wound on the reel, and by tightening or loosening the part of the restraint belt wound on the reel, the restraint belt can exert pressure on the affected limb or reduce the pressure on the affected limb through the sleeve, and use the electric heating mechanism to treat the affected limb. Apply hot compress on the limb to increase the body temperature of the edema of the affected limb and promote the swelling of the affected limb; configure a restraint belt to pressurize the affected limb when the limb is initially edema, and reduce the degree of edema through external pressure, thereby effectively preventing the edema from continuing. Extends and shortens the recovery period for swelling.

The invention discloses application of white mulberry root bark fatty oil components to preparation of a drug for treating acute lung injuries. According to the application, research on the effect of the white mulberry root bark fatty oil components on the acute lung injuries of a lipopolysaccharide induced mouse finds that the white mulberry root bark fatty oil components can lower the lung wet weight / dry weight specific value, has the effect of alleviating pulmonary edema and can remarkably reduce the content of proinflammatory factors such as TNF-alpha, IL-1beta and IL-6, it is shown under a light microscope that the white mulberry root bark fatty oil components can relieve all lung tissue pathological changes, and the lung tissue structure tends to be normal. It is indicated that the white mulberry root bark fatty oil components can alleviate pathological injuries by reducing the edema degree of LPS-caused ALI, lower the content of the proinflammatory factors such as TNF-alpha, IL-1beta and IL-6 and achieve a protection effect on LPS-caused ALI, and the mechanism of the components is worthy of further studying.

The invention belongs to the field of traditional Chinese medicine, and in particular relates to a medicinal composition for removing phlegm and removing dampness and application thereof. The pharmaceutical composition for removing phlegm and dehumidification of the present invention is prepared from the following raw material components in parts by mass: 15-30 parts of whole melon, 9-30 parts of Xiebai, 9-15 parts of Pinellia fragrans, 9-30 parts of Codonopsis Radix, and Curcuma 6‑15 servings, Coptis 2‑6 servings. Experiments on a mouse model of coronary heart disease with dampness syndrome show that the Huatan and dampness formula of the present invention can significantly improve ST segment and T wave depression in coronary heart disease phlegm damp syndrome mice, inhibit myocardial hypertrophy in coronary heart disease phlegm damp syndrome mice, and reduce CK-MB Leakage of myocardial injury enzyme spectrum of cTnT, LDH, oxLDL, protect myocardial tissue from ischemic injury, reduce cardiac enlargement caused by isoproterenol, reduce myocardial pathological changes caused by isoproterenol treatment, and maintain more myocardial cells The structure is normal, the infiltration of inflammatory cells is reduced, the membrane structure is stabilized, and the degree of edema is reduced, suggesting that the Hutanquushi Formula of the present invention has a better therapeutic effect on ischemic heart disease or angina pectoris.

The invention relates to a spiro compound used for treating cerebral apoplexy. Shown by a test result, the compound can remarkably improve nerve injury caused by ischemia reperfusion of rice undergoing ischemia reperfusion, can remarkably reduce the cerebral infarction percentage and relieve the edema degree of brain tissue of the rice and can lower the water content. Therefore, the compound has an excellent treatment effect for cerebral apoplexy, especially cerebral arterial thrombosis.